drugset / Trial / NCT00161785

Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

NCT00161785 ↗

Phase 4 Completed 340 enrolled Pfizer
RandomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess: * TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT). * TBE antibody response to a booster vaccination with FSME-IMMUN 0.5ml, by means of ELISA and NT.

Timeline

Start
2004-06
Primary completion
—
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME-IMMUN Vaccine 0.5 ml —